Lilly bets billions on focus on cancer drugs
Long a leader in diabetes and neuroscience drugs, Eli Lilly and Co. is pushing hard and spending record sums to turbocharge its oncology business, potentially a huge growth area.
Eli Lilly and Co.
Articles
Group with consumer-friendly vibe pushes drugmakers’ message
As Congress and President Donald Trump's administration aim to lower prescription drug costs, outside groups like the Alliance for Patient Access are seeking to sway the outcome.
Lilly’s $7M tax-abatement request advanced by City-County Council panel
The proposed tax abatement is related to a $91 million investment the company is making in a building at the Lilly Technology Center on Kentucky Avenue.
Lilly to introduce generic version of insulin at half off Humalog’s list price
The move comes at a time drug makers, especially those that make insulin, are facing withering criticism for raising prices.
Lilly, other insulin makers must face price-gouging lawsuit, judge rules
The suit accuses the companies of raising insulin sticker prices by more than 150 percent over five years, forcing diabetics to forgo the drug, take less insulin than needed or use expired versions
Eli Lilly negotiated its largest deal ever at breakneck speed
When the Indianapolis-based drug giant made its initial offer Dec. 20, it said it wanted to seal the deal before the J.P. Morgan Healthcare Conference, which ran Jan. 7-10 in San Francisco.
Lilly shares dip due to drug failure, lowered forecast
The Indianapolis-based pharmaceutical giant on Wednesday tempered expectations for its earnings in 2019 after a promising cancer drug failed to pan out and the firm prepared for big acquisition.
Harvard study involving Anthem unit finds older insulins are both safe, cheaper
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
Lilly cancer drug shouldn’t be started in new patients, FDA says
Lartruvo shouldn’t be started in new patients, and those patients already taking it should ask their doctors if they should continue, U.S. regulators said, following a key study that failed to show the medicine prolonged lives.
Promising Lilly cancer drug fails in disappointing trial, shares fall 3 percent
Analysts had predicted that Lartruvo could eventually ring up as much as $600 million in annual sales. Eli Lilly and Co. now says it will suspend promotion of the drug.
Lilly wins national award for advancing women in the workplace
The Catalyst Award recognizes companies that excel in addressing recruitment, development and advancement of women. Today, nearly half of Lilly's senior leadership is female, up from 20 percent four years ago.
Would-be dealmakers warn of M&A, IPO delays due to shutdown
A prolonged shutdown could muddle Eli Lilly and Co.’s plan to unload its stake in Elanco Animal Health Inc., the unit it spun off last year, Lilly CEO Dave Ricks said.
Lilly to disclose more information about drug pricing
Eli Lilly and Co. won’t put the price of its prescription drugs in television ads, as the Trump administration has called for pharmaceutical companies to do, but will begin promoting a website where prices are available.
Lilly execs: $8B acquisition feeds into cancer drug strategy
Drug industry analysts on Monday applauded Eli Lilly and Co.’s pending $8 billion cash deal to buy a startup that focuses on oncology, which has become a prime focus for the pharma giant in the last year.
In its biggest takeover ever, Lilly buying cancer drug startup for $8 billion
Connecticut-based Loxo Oncology, which was founded in 2013 and went public a year later, has a cancer drug in development that recently received U.S. Food and Drug Administration "breakthrough therapy" status.
Big pharma stocks among top performers in 2018
Pharmaceutical giants Merck & Co. and Pfizer Inc. were kings of the Dow Jones industrial index during the year, while Eli Lilly and Co. was among the 20 largest gainers on the S&P 500.
Trump Medicare plan targets drugs from Eli Lilly, others
Makers of antidepressants and antipsychotics like Indianapolis-based Eli Lilly and Co., AstraZeneca, Pfizer, Allergan, Bausch Health and Otsuka Holdings might face new challenges and may be deterred from price hikes.
Rising fear among Asians leads Eli Lilly to rethink employee groups
New employees at Eli Lilly and Co. get a letter encouraging them to join one of the pharmaceutical firm’s affinity groups. There’s one for African Americans, one for Latino employees—and four for Asians.
Eli Lilly considering sale of China assets to raise cash
Indianapolis-based Lilly is working with advisers to gauge interest in selling off a selection of older drugs for antibiotics and central nervous system diseases in China.
Janitor uprising highlights tensions over outsourcing
Nearly 650 Indianapolis-area janitors represented by the Service Employees International Union work for just eight firms that clean downtown office buildings.